Opiates are known to function as immunomodulators, in part by effects on T cells. However, the signal transduction pathways mediating the effects of opiates on T cells are largely undefined. To determine whether pathways that regulate free intracellular calcium ([Ca2+] [Ca2+]i by more than 50%v and eliminated the second phase of calcium mobilization. Additionally, the effect of DADLE on forskolin-stimulated cAMP production was determined. DADLE reduced cAMP production by 70%o (IC50 of -10-1" M), and pertussis toxin inhibited the action of DADLE. Thus, the DOR expressed by a transfected Jurkat T-cell line is positively coupled to pathways leading to calcium mobilization and negatively coupled to adenylate cyclase. These studies identify two pertussis toxin-sensitive, G proteinmediated signaling pathways through which DOR agonists regulate the levels of intracellular messengers that modulate T-cell activation.
Both neuroendocrine peptides and biogenic amines are established immunomodulators. These agents interact with seven transmembrane G protein-coupled receptors that are expressed by mononuclear cells involved in host defense and immunity. Neuropeptides such as substance P (1) and endocrine peptides like adrenocorticotropin (ACTH; secreted by the anterior pituitary gland) modify various immune functions through receptors similar to those found in the central nervous system (2, 3) . Norepinephrine, a monoamine secreted from the axon terminals innervating lymphoid tissue (4), stimulates cAMP production through the 132-adrenergic receptors present on mononuclear cells. The enkephalins are an example of opioid peptides that most commonly originate from neural tissues, yet are also synthesized by immune cells for the purpose of autocrine/paracrine regulation (5-7). Thus, peptides and biogenic amines secreted from neural, endocrine, and immune tissues directly impact immune function.
Functional and structural studies provide evidence of opioid receptors on lymphocytes. Both enkephalins and synthetic opioid peptide agonists selective for the delta subtype of opioid receptor (DOR) were shown to rapidly stimulate chemotaxis by highly purified human peripheral blood T cells (8) . The opioid receptor antagonist, naloxone, blocked these effects and also inhibited the chemotaxis induced by selective mu opioid receptor agonists. In another study, proliferation of highly purified murine splenic T cells was inhibited by DOR agonists (9) . Recently, it was reported that simian peripheral blood mononuclear cells express the DOR mRNA originally cloned from hybrid neural cells and present within the central nervous system (10) Expression of the neuronal mu opioid receptor in human peripheral blood CD4+ T cells was also shown by sequencing a partial transcript derived by reverse transcription and polymerase chain reaction (11) . Taken together, both pharmacological and molecular approaches indicate that lymphocytes obtained from human, simian, and murine tissues express opioid receptors that are similar to those present in neural tissues. In addition, opioid peptides such as j3-endorphin bind to and modulate lymphocyte function through nonopioid receptors (12) (13) (14) .
Opiate modulation of both humoral and cell-mediated immunity is due in part to effects on T lymphocytes (15) (16) (17) . DOR agonists, such as deltorphin, have been shown to modulate crucial events involved in T-cell activation, including (i) the proliferative response to crosslinking the CD3 complex associated with the T-cell antigen receptor (TCR) and (ii) the production of interleukin 2, which is involved in progression from Gl to S phase of the cycle cycle. At nanomolar concentrations, deltorphin modulated proliferation and interleukin 2 accumulation by both highly purified murine splenic CD4+ and CD8+ T cells (9) , and the specific DOR antagonist, naltrindole (18) , reversed the effect of deltorphin. Since preincubation with delta opioid agonists was required before stimulation with the anti-CD3 antibody, these studies (9) provide evidence for functional DORs on quiescent splenic CD4+ and CD8+ T-cells.
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and Raf, key effectors in pathways that mediate TCR signaling. In lymphocytes, cAMP analogs and forskolin have been shown to retard the generation of IP3 by inhibiting the activity of PLC-,yl (25) (26) (27) . Studies in a nonlymphoid cell line identified the Ras-dependent activation of Raf-1 as sensitive to inhibition by increased intracellular cAMP concentration (28) . Interleukin 2 production, T-cell cycle progression and T-cell proliferation are also known to be suppressed by increased intracellular cAMP concentration (25, 29) . Although the mechanism(s) underlying suppression of interleukin 2 production and T-cell proliferation have not been fully clarified, the inhibitory effects of cAMP on both PLC--yl and the Ras-Raf interaction may contribute to impaired signaling through the TCR.
To understand DOR-mediated signal transduction in T-cells and the consequences of this for T-cell function, the cDNA encoding this receptor was stably expressed in Jurkat cells, a human T-cell line. This model was used to determine whether intracellular calcium and cAMP mediate signaling through the neuronal DOR expressed by T-cells. In contrast to studies using splenocytes or even highly purified T-cells, which are both heterogenous with respect to phenotype, function and responsiveness to opioids, this model can advance our understanding of opioid immunomodulation by clarifying the mechanism(s) of DOR-mediated signal transduction in a homogenous population of T-cells. pertussis toxin on deltorphin-stimulated calcium mobilization in DOR-Ju.1 cells was studied.
MATERIALS AND METHODS

Reagents
Cells were treated for 6 hr with pertussis toxin (10 or 100 ng/ml) and then stimulated with deltorphin 10-7 M. Fig. 4 shows that both concentrations of pertussis toxin inhibited 90% of the deltorphin-induced increase in peak I [Ca2+]i and produced a similar reduction in the [Ca2+], levels that follow peak I. In contrast, the ,B subunit of pertussis toxin (membrane binding subunit), at concentrations as high as 1 ,ug/ml, was ineffective, and intact pertussis toxin did not reduce ionomycin-induced calcium mobilization (data not shown). Therefore, the inhibitory effect of intact pertussis toxin on deltorphininduced calcium mobilization was specific.
EGTA Attenuates Deltorphin-Stimulated [Ca2+], Mobilization. In lymphocytes, IP3-dependent calcium mobilization may involve both the release of calcium from intracellular stores and the influx of extracellular calcium (22, 37 ng/ml) or the ,B subunit of pertussis toxin for 6 hr and then stimulated with forskolin + DADLE 10-11 or 10-9 M (n = 3/treatment). These concentrations of peptide reduced cAMP production to 65.0 + 6.8% (P < 0.05) and 33.0 ± 1.2% (P < 0.01) of control (forskolin alone), respectively. The corresponding values obtained after pretreatment with pertussis toxin were 116.0 + 8.5% and 101.0 ± 6.2% of control. The ,3 subunit of pertussis toxin was ineffective (63.3 ± 3.0% and 34.7 + 3.0% of control). Proc. Natl. Acad. Sci. USA 93 (1996) may interact with second messenger pathways that are activated by the TCR, modulating the production and/or action of cell cycle regulators, such as interleukin 2. This is supported by the observation that deltorphin modulated the secretion of interleukin 2 by highly purified normal splenic CD4+ T-cells that were stimulated through the TCR (9) .
Following TCR activation, the initial mobilization of intracellular calcium is stimulated by the IP3 generated by PLC--yl (20) . The subsequent influx of extracellular calcium may also involve this pathway, which is independent of G proteins (37, 39, 40) . In contrast, both phases of the calcium response to deltorphin are pertussis toxin-sensitive, indicating the involvement of the Gi or Go families of G proteins. The 3y subunits associated with these G proteins are known to activate PLC-, 3 isozymes, such as PLC-f1, which has been identified in Jurkat cells, resulting in the synthesis of IP3 (41) (42) (43) . Therefore (57) . Therefore, DOR agonists may modulate normal T-cell activation through the coupling of DOR to the signal transduction pathways shown herein.
